WUXI BIO (02269.HK) +0.680 (+3.872%) Short selling $161.49M; Ratio 20.882% opened 3.6% higher at $17.5 today (14th). It last stood at $17.8, up 5.33%, with 12.7161 million shares traded, involving $223 million. The presentation of the company's 2025 annual healthcare conference disclosed that the group's business and financial position remained strong. The group was confident in realizing the projected revenue growth last year, while anticipating to achieve accelerated revenue growth YoY this year.Related NewsCMBI Lifts WUXI BIO (02269.HK) TP to $24.24 as Demand Brings Good 2025 OutlookThe group added 151 new projects last year, bringing the total number of projects to 817. Moreover, seven global projects in molecular research services were empowered through the Research(R) platform last year and were entitled to receive approximately US$140 million in the near future, with a potential total collection of approximately US$2.3 billion (assuming all milestones of these global projects are met).(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-01-24 16:25.)